| 阿衣娜扎尔·艾合买提,李雨婧,邹沛辰,王 珏,赵雪雯,沙 攀,朱 亮,唐亚斌.基于液相色谱串联高分辨质谱技术的小细胞肺癌血浆代谢组学研究[J].,2024,(11):2001-2008 |
| 基于液相色谱串联高分辨质谱技术的小细胞肺癌血浆代谢组学研究 |
| Plasma Untargeted Metabolomics of Small Lung Cancer Cell Based on Liquid Chromatography-High Resolution Mass Spectrometry |
| 投稿时间：2023-12-19 修订日期：2024-01-16 |
| DOI：10.13241/j.cnki.pmb.2024.11.001 |
| 中文关键词: 小细胞肺癌 血浆 代谢组学 高分辨质谱 |
| 英文关键词: Small Cell Lung Cancer Plasma Metabolomics High Resolution Mass Spectrometry |
| 基金项目:国家自然科学基金项目（82103050） |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘要 目的：对小细胞肺癌患者血浆开展质谱代谢组学研究，表征其基线代谢特征，为小细胞肺癌诊疗提供基础代谢数据及线索。方法：基于液相色谱串联四极杆飞行质谱技术，以45例小细胞肺癌患者和53例对照组（健康人群）血浆为研究对象，进行非靶向代谢组学分析及代谢表征。结果：与对照组相比，基线期小细胞肺癌患者血浆代谢发生显著改变，共发现113种差异代谢物，其中2'-deoxyguanosine 5'-monophosphate（FC=9.17）、cyclic adenosine monophosphate（FC=7.72）、inosine（FC=6.38）等59种代谢物水平升高，2-aminobenzoic acid（FC=0.24）、glutathione（FC=0.27）、xanthine（FC=0.29）等54种代谢物水平下降，差异代谢通路主要涉及色氨酸等氨基酸代谢。结论：小细胞肺癌患者基线血浆代谢轮廓与健康人群存在显著差异，相关差异代谢物及通路的挖掘有助于推动小细胞肺癌新型诊断标志物发现和代谢干预靶点的揭示，改善其治疗手段有限等现状。 |
| 英文摘要: |
| ABSTRACT Objective: Conduct metabolomic research on the plasma of patients with small cell lung cancer to characterize their baseline metabolic characteristics and provide basic metabolic data and clues for the treatment of small cell lung cancer. Methods: Based on liquid chromatography couple with quadrupole time-of-fight mass spectrometry, plasma untargeted metabolomics studies and metabolic characterization on 53 controls (healthy people) and 48 patients with small cell lung cancer were developed. Results: The plasma metabolism was significantly altered in patients with small cell lung cancer at baseline compared to controls and a total of 113 differential metabolites were identified. The 59 up-regulated metabolites such as 2'-deoxyguanosine 5'-monophosphate (FC=9.17), cyclic adenosine monophosphate (FC=7.72), and inosine (FC=6.38), and 54 down-regulated metabolites such as 2-aminobenzoic acid (FC=0.24), glutathione(FC=0.27) and xanthine(FC=0.29), mainly participated in amino acid metabolism. Conclusion: Metabolic profiling was changed significantly between patients with small cell lung cancer and controls. The discovery of relevant differential metabolites and pathways will help promote the development of new targeted drugs for small cell lung cancer, thereby improving the current situation of limited treatment options and lack of targeted treatments. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
